Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: A true “Oligoastrocytoma”?

Acta Neuropathologica

Volumn 129, Issue 1, 2015, Pages 151-153

  Huse, Jason T ^a   Diamond, Eli L ^a   Wang, Lu ^a   Rosenblum, Marc K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE;

ADULT; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; CONTRAST ENHANCEMENT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IONIZING RADIATION; LETTER; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUMOR VOLUME; BRAIN TUMOR; CLASSIFICATION; GENETICS; MALE;

ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; HUMANS; MALE; OLIGODENDROGLIOMA;

EID: 84929629913     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-014-1359-y     Document Type: Letter

References (11)

1. Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ et al (2014) Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32:783–790. doi:10.1200/JCO.2013.49.3726
2. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Marie SK et al (2012) Frequent ATRX, CIC, and FUBP1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722
3. Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER, Heguy A, Petrini JH, Chan TA, Huse JT (2012) Whole exome sequencing identified ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3:1194–1203
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109
5. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart CG et al (2014) International society of neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (in press)
6. Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Wiestler OD et al (2002) Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 161:313–319. doi:10.1016/S0002-9440(10)64183-1
7. Qu M, Olofsson T, Sigurdardottir S, You C, Kalimo H, Nister M, Smits A, Ren ZP (2007) Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas. Acta Neuropathol 113:129–136. doi:10.1007/s00401-006-0142-0
8. Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, Jones DT, Pfister SM, Herold-Mende C, Wick W et al (2014) Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 128:551–559. doi:10.1007/s00401-014-1326-7
9. van den Bent MJ (2010) Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol 120:297–304. doi:10.1007/s00401-010-0725-7
10. Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451. doi:10.1007/s00401-013-1156-z
11. Wilcox P, Li CC, Lee M, Shivalingam B, Brennan J, Suter CM, Kaufman K, Lum T, Buckland ME (2014) Oligoastrocytomas: throwing the baby out with the bathwater? Acta Neuropathol. doi:10.1007/s00401-014-1353-4